摘要
目的:探讨埃罗替尼靶向治疗前后非小细胞肺癌患者外周血CD4+、CD8+和CD56+的表达及其临床意义。方法:流式技术检测30例EGFR突变的非小细胞肺癌患者埃罗替尼一线靶向治疗前后,外周血T细胞亚群的表达情况及疗效。结果:靶向治疗1个月后,与治疗前相比较非小细胞肺癌患者外周血T细胞亚群CD4+、CD8+以及CD56+表达数量有统计学差异(P<0.05)。其中,CD4+表达上升,CD8+和CD56+表达下降。结论:埃罗替尼靶向治疗可以改善非小细胞肺癌患者细胞免疫功能,观察外周血T细胞亚群表达情况有助于评价埃罗替尼靶向治疗的疗效和预后。
Objective： To explore the expression and clinical significance of T lymphocyte subsets, including CD4^＋, CD8^＋, CD56^＋ in peripheral blood of non-small-cell lung cancer patients with erlotinib target therapy. Methods： 30 patients with Genetic variations in EGFR who lxeated by erlotinib were entered into the study and venous blood was obtained from them. Percentages of CD4^＋, CD8^＋ and CD56 ^＋ were measured by flow cytometry. Results： Compared to pre-therapy, 30 patients with non-small-cell lung cancer had significant differences in the percentage s of CD4^＋, CD8^＋and CD56^＋ T cells （P〈0.05）. CD4^＋ were significantly increased while CD8^＋ and CD56^＋ were decreased in patients who were treated with erlotinib after one month. Conclusion： Erlotinib could improve the Cellular Immune Function in the treatment of patients with non-small-cell lung cancer. The percentages ofT lymphocyte subsets in Peripheral blood is contribute to evaluating and analyzing the curative effect and prognosis.
出处
《现代生物医学进展》
CAS
2013年第32期6328-6331,共4页
Progress in Modern Biomedicine
